Treatment of FIGO 2018 stage IIIC cervical cancer with different local tumor factors
Yanna Ye,Zhiqiang Li,Shan Kang,Yongxiu Yang,Bin Ling,Li Wang,Jilong Yao,Pengfei Li,Xueqin Wang,Shipeng Gong,Huijian Fan,Yanxiang Kong,Yuye Cao,Jinghe Lang,Ping Liu,Chunlin Chen
DOI: https://doi.org/10.1186/s12885-023-10801-w
IF: 4.638
2023-01-01
BMC Cancer
Abstract:Background To compare the oncological outcomes of patients with FIGO 2018 stage IIIC cervical cancer (CC) involving different local tumor factors who underwent abdominal radical hysterectomy (ARH), neoadjuvant chemotherapy and radical surgery (NACT), or radical chemoradiotherapy (R-CT). Methods Based on tumor staging, patients with stage IIIC were divided into T1, T2a, T2b, and T3 groups. Kaplan–Meier and Cox proportional hazards regression analysis were used to compare their overall survival (OS) and disease-free survival (DFS) of 5 years. Results We included 4,086 patients (1,117, 1,019, 869, and 1,081 in the T1, T2a, T2b, and T3 groups, respectively). In the T1 group, NACT was correlated with a decrease in OS (hazard ratio [HR] = 1.631, 95% confidence interval [CI]: 1.150–2.315, P = 0.006) and DFS (HR = 1.665, 95% CI: 1.255–2.182, P < 0.001) than ARH. ARH and NACT were not correlated with OS ( P = 0.226 and P = 0.921) or DFS ( P = 0.343 and P = 0.535) than R-CT. In the T2a group, NACT was correlated with a decrease in OS (HR = 1.454, 95% CI: 1.057–2.000, P = 0.021) and DFS (HR = 1.529, 95% CI: 1.185–1.974, P = 0.001) than ARH. ARH and NACT were not correlated with OS ( P = 0.736 and P = 0.267) or DFS ( P = 0.714 and P = 0.087) than R-CT. In the T2b group, NACT was correlated with a decrease in DFS (HR = 1.847, 95% CI: 1.347–2.532, P < 0.001) than R-CT nevertheless was not correlated with OS ( P = 0.146); ARH was not correlated with OS ( P = 0.056) and DFS ( P = 0.676). In the T3 group, the OS rates of ARH ( n = 10), NACT ( n = 18), and R-CT ( n = 1053) were 67.5%, 53.1%, and 64.7% ( P = 0.941), and the DFS rates were 68.6%, 45.5%, and 61.1%, respectively ( P = 0.761). Conclusion R-CT oncological outcomes were not entirely superior to those of NACT or ARH under different local tumor factors with stage IIIC. NACT is not suitable for stage T1, T2a, and T2b. Nevertheless ARH is potentially applicable to stage T1, T2a, T2b and T3. The results of stage T3 require confirmation through further research due to disparity in case numbers in each subgroup.